C4 Therapeutics, Inc.

CCCC

$3.73

-0.40%

2026-09-04 11:58:22 EDT-$0.01

Salud

Biotecnología

NASDAQ

Negociación activa

C4 Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que se centra en descubrir y desarrollar candidatos terapéuticos innovadores. Su estrategia ...

Perfil del CEO de CCCC

Andrew Hirsch

C4 Therapeutics, Inc.

Antigüedad 6yRiesgo por persona clave: Medium

Andrew Hirsch has successfully professionalized C4 Therapeutics since the IPO, steering it through critical development stages via disciplined partnership strategies. While market capitalization has suffered, the underlying R&D focus and...

Riesgo clave

•Clinical development failure

•Sector volatility

•Funding dependence

Viento de cola clave

•Validation through pharma partnerships

•Clinical progress of TPD pipeline

Andrew Hirsch

C4 Therapeutics, Inc. (CCCC) · NASDAQ

Antigüedad 6 añosCEO no fundadorRiesgo por persona clave: Medium

MBA

andrew-hirsch-a3528b1

Historia de origen

Andrew Hirsch, a seasoned life sciences executive, transitioned from his roles in finance and operations to lead C4 Therapeutics during its critical pivot to the public markets.

Primer gran salto: Executive leadership roles spanning finance and operations in life science companies.

Camino al CEO: Hirsch brought substantial experience from prior leadership roles before joining C4 Therapeutics in September 2020, successfully guiding the company through its transition to a publicly traded entity shortly after his appointment.

Visión original: To advance the company's proprietary targeted protein degradation (TPD) platform toward clinical-stage validation.

Andrew Hirsch joined C4 Therapeutics in 2020 as CEO, bringing decades of corporate, financial, and operational experience to the company. His leadership has focused on maturing the clinical development pipeline and fostering strategic pharmaceutical partnerships, such as the 2026 collaboration with Roche, to build sustainable value for the TPD technology platform.

biotech executiveoperational leader

Tesis de inversión

Vientos de cola

Validation through pharma partnerships

Clinical progress of TPD pipeline

Riesgos clave

Clinical development failure

Sector volatility

Funding dependence

Historial profesional

Career built on senior financial and operational leadership within the biotechnology and life sciences sector.

C4 Therapeutics, Inc.

Iniciativa: President and CEO

Periodo: 2020–Present

Evento: Led company through IPO, established major pharma collaborations (Roche, Calico), and advanced clinical pipeline.

Resultado: Share price volatility reflecting broader biotech market trends.

life sciencesbiotech management

Rendimiento de la empresa

Hirsch has navigated the company through early clinical stages and successfully maintained active R&D partnerships despite significant stock price headwinds.

Ingresos: Revenue fluctuates heavily based on the achievement of milestones within pharmaceutical collaborations.

Rentabilidad: Operating as a clinical-stage biotech, the company remains pre-profitable with focused R&D cash burn.

Acción: The stock has experienced significant downward pressure since the 2021 highs, consistent with sector-wide corrections for early-stage TPD companies.

•Successful IPO in 2020

•Strategic partnership with Roche (2026)

•Maturation of clinical pipeline

•Significant decline in market capitalization since 2021 peak

clinical-stagecollaboration-driven

Capacidad de gestión

Operator-focused leader known for building professional management structures suited for public biotech companies.

Estilo: Professional operator

Hirsch emphasizes operational excellence, financial discipline, and the systematic maturation of clinical assets. He has successfully recruited an experienced executive bench to support the company's research and partnership strategies.

operational excellenceteam building

Asignación de capital

Highly disciplined in leveraging R&D collaboration milestones to fund operations while minimizing dilution.

Focus on cash runway extension through strategic non-dilutive partnerships.

Roche Collaboration (2026): Advanced DAC modality research and potential milestone funding.

Hirsch has prioritized capital efficiency by utilizing corporate collaborations to underwrite costly drug discovery and early-stage development, attempting to balance R&D investment with shareholder cash preservation.

capital efficiencynon-dilutive funding

Financiación y captación

Expert in navigating the public capital markets and securing high-value corporate collaborations.

IPO: Successfully listed on NASDAQ in 2020.

Dilución: moderate

Hirsch has successfully balanced public financing with strategic non-dilutive capital. He has steered the company through the complex funding requirements of a clinical-stage biotechnology business while maintaining investor confidence.

IPO track recordcollaboration funding

Gobernanza y control

Standard corporate governance structure with an active and independent board of directors.

The company operates under standard governance protocols for a publicly traded US biotech firm. The board is focused on fiduciary duty and overseeing the transition of the company through clinical maturity.

standard governance

Salud y sucesión

No public concerns reported regarding health or succession planning.

Estado de salud: no public concerns

Riesgo por persona clave: Medium

Standard professional leadership succession policies generally apply.

no concerns

I+D y visión tecnológica

Strong focus on advancing the targeted protein degradation (TPD) platform.

High, typical for clinical-stage biotech development.

Targeted Protein Degradation (TPD): Ongoing clinical development.

Highly focused on specific modalities within the TPD space.

•Early focus on DAC modality and strategic partnerships.

Hirsch has maintained the company's focus on its proprietary platform, resisting broader diversification to ensure deep expertise in TPD and related modalities. R&D efforts are heavily influenced by partner needs and scientific feasibility.

TPD specializationR&D focus

Captación de talento

Has successfully recruited and retained a strong C-suite and leadership team in a competitive biotech market.

High; depth of experience in R&D and corporate development.

Retención: strong

Hirsch has cultivated a team that balances scientific rigour with corporate maturity, essential for steering a public company through the regulatory and commercial challenges of drug development.

executive recruitmentculture of excellence

Fortalezas

Demonstrated capability in leading strategic partnerships and maturing public company operations.

Strategic Leadership: Securing key pharmaceutical collaborations like Roche.

strategic partnershipsoperational discipline

Debilidades y fallos

Challenges in sustaining market capitalization and investor sentiment in a volatile macro environment.

Market Valuation

Significant share price decline from 2021 peak.

Ejemplo: CCCC 2021 vs 2026 trading range.

market valuation pressure

Marketing y marca

Maintains a professional, high-credibility brand presence focused on technical validation and institutional partnerships.

Positioned as a premier developer in the TPD modality rather than a generalist biotech.

The marketing strategy is focused on building institutional confidence among investors and research partners through technical clarity, transparent clinical updates, and validation through partnerships with top-tier firms like Roche and Calico.

institutional credibilitymodality-focused

PR y comunicación

Consistent and clear communicator with a focus on scientific progress and corporate development milestones.

Reputación mediática: positive

Hirsch maintains a high-quality communication standard, delivering clear messages during earnings calls and investor presentations. His focus is on long-term value creation through the scientific validation of the TPD platform rather than short-term price movements.

clear communicationinvestor relations

Cadena de suministro de CCCC

Upstream / Downstream / Proxy

Upstream

China Baowu Steel Group (Baoshan Iron & Steel)SSE:600019HBIS Group (Hesteel)Anhui Conch Cement Company Ltd.SEHK:0914 China National Building Material Co., Ltd. (CNBM)SEHK:3323SANY Heavy Industry Co., Ltd.SSE:600031XCMG Construction Machinery Co., Ltd.SZSE:000425Zoomlion Heavy Industry Science & Technology Co., Ltd.SZSE:000157Shanghai Zhenhua Heavy Industries Co., Ltd. (ZPMC)SSE:600320CCCC Dredging (Group) Co., Ltd.Vale S.A.NYSE:VALE BHP Group Ltd.NYSE:BHP Rio Tinto GroupNYSE:RIO Weichai Power Co., Ltd.SEHK:2338 Cummins Inc.NYSE:CMISinopec (China Petroleum & Chemical Corp.)SSE:600028

Downstream

Ministry of Transport, People's Republic of ChinaProvincial Transportation Departments (various Chinese provinces)China State Railway Group Co., Ltd.Local Chinese Municipal GovernmentsSri Lanka Ports AuthorityGovernment of Pakistan (CPEC Authority)Government of KenyaGovernment of IndonesiaGovernment of MalaysiaChina Harbour Engineering Company (CHEC)China Road and Bridge Corporation (CRBC)China Development Bank (CDB)Export-Import Bank of China (Exim Bank)

Empresas proxy

China State Construction Engineering Corp. (CSCEC)SSE:601668China Railway Group Ltd. (CREC)SSE:601390China Railway Construction Corp. (CRCC)SSE:601186Vinci SAEPA:DG

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal